Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iSPASM
NCT03691727Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in aneurysmal subarachnoid hemorrhage (SAH) comparing tirofiban hydrochloride (AGGRASTAT®) with Standard of Care Control Arm (2 arms). Primary endpoints: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) and Number of Participants With Delayed Cerebral Ischemia / Clinical Vasospasm. Started Jan 2019; status: completed.
02
Drugs
tirofiban
03
Conditions
aneurysmal subarachnoid hemorrhage (SAH)
Beyond the preview
Go deeper on NCT03691727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03691727.